At the recent CSH worm meeting we reported that mutations in the gene
egl-16 1) can promote male development in XX animals, and 2) have phenotypes which are sensitive to X-chromosome dosage, affecting XX but not XO animals. The former assertion was based on the observations that a)
egl-16(
n485.Y4)/Df XX animals display an incompletely penetrant Tra phenotype, and b) in double mutant strains,
egl-16(
n485) enhances the sexual transformation phenotypes of weakly masculinizing mutations in the genes
tra-2 and
egl-41. The latter assertion was based on the fact that
her-1(
e1520);
egl-16(
n485) XX hermaphrodites are Egl and slightly short, while XO hermaphrodites are essentially wild-type. Likewise,
tra-1(
e1099.
e1488); 85) XX animals are short pseudomales with abnormal bursae, while XO males are wild-type in length and have normal bursae. Since the meeting, we have extended our understanding of
egl-16 in several ways: The sexual transformation phenotype of
egl-16 is effected through the major sex determination pathway. XX animals homozygous for the weak allele
tra-2(
n1106) are not visibly transformed but are merely HSN Egl hermaphrodites. The vast majority of animals of the genotype
tra-2(
n1106)
unc-4(
e120);
egl-16(
n485), however, are either visibly sexually transformed or sterile; a homozygous strain of this genotype cannot be maintained. To test whether this enhancement of sexual transformation caused by the
egl-16 mutation occurs through the major sex determination pathway, we constructed the triple mutant
her-1(
e1520);
tra-2(
n1106)
unc-4(
e120); 85). The
her-1 mutation blocks sexual transformation in this self-fertile Egl hermaphrodite strain, indicating that the
egl-16 mutation promotes masculinization directly through the major sex determination pathway rather than via some peripheral mechanism. Arguing from epistasis,
egl-16 acts upstream of
her-1, perhaps by modulating
her-1 activity.
egl-16(
n485) disrupts dosage compensation in XX animals. The fact that
egl-16(
n485) affects XX but not XO animals regardless of sexual phenotype suggested that this mutation may disrupt dosage compensation, producing an elevated level of X-linked gene expression in XX animals. This hypothesis was tested using both the biochemical assay for X- specific mRNA levels (Meyer and Casson) and the morphological assay for
lin-14 expression (Plenefisch and De Long) described in this issue.